<DOC>
	<DOCNO>NCT02915250</DOCNO>
	<brief_summary>This two-centre , randomised , double-blind , double-dummy , 3-treatment , 3-period cross-over study use standardise solid meal test subject type 2 diabetes investigate postprandial glucose control BioChaperone® Combo compare Humalog® Mix25 simultaneous subcutaneous injection Humalog® Lantus® three separate dose visit .</brief_summary>
	<brief_title>A Trial Compare Post Prandial Blood Glucose Control BioChaperone® Combo With Humalog® Mix25 With Simultaneous Injections Humalog® Lantus® Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>This two-centre , randomised , double-blind , double-dummy , 3-treatment , 3-period cross-over study use standardise solid meal test subject type 2 diabetes investigate postprandial glucose control BioChaperone® Combo compare Humalog® Mix25 simultaneous subcutaneous injection Humalog® Lantus® three separate dose visit . Furthermore , study aim compare pharmacokinetic ( PK ) profile three different study treatment . During dose visit , subject give 3 dos IMP three consecutive day ( Day 1 , Day 2 Day 3 ) . Dosing Day 2 Day 3 follow standardise solid meal test .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<criteria>Male female subject age 1870 year ( inclusive ) Type 2 diabetes mellitus ( diagnose clinically ) ≥ 12 month HbA1c level 7.5 % 9.5 % ( inclusive ) Body mass index 20.0 40.0 kg/m2 ( inclusive ) Treated daily injection insulin glargine U100 ≥ 3 month prior screen Type 1 diabetes mellitus Known suspect allergy IMPs related product Previous participation trial . Participation define randomise . Receipt medicinal product clinical development within 60 day prior trial . Clinically significant abnormal haematology , biochemistry , urinalysis coagulation screening test , judge Investigator consider underlying disease Supine blood pressure screen outside range 90160 mmHg systolic 5095 mmHg diastolic and/or rest supine heart rate outside range 5090 beat per minute . This exclusion criterion also pertain subject antihypertensive . Current treatment premixed intermediate insulin product , long act insulin insulin glargine U100 . The use short rapid act prandial insulin product allow provide use stable ≥ 3 month prior screen . Use GLP1 receptor agonists oral antidiabetic drug ( OADs ) stable intake metformin alone metformin combination DPP4 inhibitor within 4 week prior screen Women child bear potential willing use contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>